Clinical Trials Browser

Phase 2/3 × Recruiting × Multiple Myeloma × Clear all

NCT07095452 2026-05-27

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 2/3 Recruiting

660 enrolled

Plasma cell

Multiple Myeloma

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

30 enrolled

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT04513639 2025-03-20

The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

Phase 2/3 Recruiting

176 enrolled

Plasma cell

Multiple Myeloma

NCT06879379 2025-03-17

KPD Consolidation After ASCT in NDMM Patients

Phase 2/3 Recruiting

202 enrolled

Plasma cell

Multiple Myeloma